Civitas is developing an inhaled form of the drug levadopa that is currently used by Parkinson’s patients in tablet form.

Irish private equity group Fountain Healthcare is one of the big winners following the sale of a company that has developed a experimental therapy fo(...)

Manus Rogan of Fountain Healthcare and Peter Crosby, chief executive of Mainstay Medical.

Back pain group Mainstay Medical has floated in Paris and Dublin in an IPO that values the early stage medical device company (...)

Mainstay Medical chief executive Peter Crosby.

Irish medical device company Mainstay Medical plans to raise up to €26.4 million in a stock market flotation (...)

 Peter Crosby, chief executive of Mainstay Medical. Photograph: Nick Bradshaw

Mainstay Medical, an Irish-based group focused on addressing chronic back pain, has announced it plans to float on the (...)

Genable Technologies founder and director Prof Jane Farrar. Photo: Aidan Crawley

Genable Technologies, a Dublin company targeting genetic diseases causing blindness, has announced a collaboration with US biopharma group Spar(...)

Trials are starting initially in Australia as the regulatory path there was considered quicker to negotiate, according to the company’s Australian chief executive, Peter Crosby.

It has taken three years to get a product to trials: Mainstay Medical hopes that within another two, it will have a device on the market in Eur(...)

“The results are, for us at least, pretty exciting. They show that the therapy that’s delivered by our product appears to work and the results have certainly captured the attention of the clinical community with which we work,” said Mainstay chief executive Peter Crosby.

Mainstay Medical, an Irish medtech company targeting chronic lower back pain, is starting clinical trials on its Reactiv8 implantable device. (...)

[From left  to right] Professor Helen Sheridan, Trino Therapeutics, Professor Neil Frankish, Trino Therapeutics and Dr Ena Prosser, Fountain Healthcare Partners. Photograph: Nick Bradshaw

A Trinity College spinout company developing a new class of drugs to tackle inflammatory diseases has raised over €9 million to fund clinical trials.D(...)